Translating Scientific Breakthroughs into Promise for Patients

From discovery through commercialization, all of us at Ardelyx are driven to advance targeted therapies where significant medical needs persist. We have developed a unique and innovative platform that has enabled the discovery of new biological mechanisms and pathways to create targeted, first-in-class, oral, small molecule therapies to meet these needs. Our lead candidate, tenapanor, is currently under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

With Integrity and Dedication, We Make a Difference for Patients

Join Us

We are… Passionate. Fearless. Dedicated. Inclusive!

Patients & Families

Translating scientific breakthroughs into promise for patients.

For Investors

Creating value from

Recent News

September 15, 2020

Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of...

September 8, 2020

Ardelyx to Participate in Three Upcoming Investor Conferences in September

August 6, 2020

Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business...